STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3654 by analyst upside · 2026-06-27
CNTA
Centessa Pharmaceuticals plc
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
-0.6%
implied upside to consensus target
Current Price $40.5
Consensus Target $40.25
Bull Target $45.0
Bear Target $38.0
Analysts Covering 4
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
2
Hold
1
Sell
1
52-Week Low $12.75
52-Week High $40.56
YTD Return +71.0%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E -22.8x
EPS (TTM) $-1.78
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $12.75
52-Week High $40.56
Current Price $40.5
Bear Target $38.0
Bull Target $45.0
● Now $40.5 ● Target $40.25
TRADING DATA
Avg Volume 2.9M
YTD Return +71.0%
Analyst Count 4
Consensus Hold
Upside to Target -0.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Centessa Pharmaceuticals plc (CNTA) is currently trading at $40.5 with a Wall Street consensus price target of $40.25, which is 0.6% below the current price over the next 12 months. 4 analysts currently cover CNTA, with a consensus rating of Hold - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $45.0, while the most cautious has a target of $38.0.

CNTA operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 71.0% year-to-date and is currently trading near the upper end of its 52-week range of $12.75 – $40.56.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CNTA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo ↓ Downgrade
Overweight → Equal-Weight 2026-04-20 Building track record
Guggenheim ↓ Downgrade
Buy → Neutral 2026-04-02 62% win rate (8 calls)
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-04-01 29% win rate (7 calls)
Wolfe Research ↓ Downgrade
Outperform → Peer Perform 2026-03-31 Building track record
Needham ↓ Downgrade
Buy → Hold 2026-03-31 20% win rate (5 calls)
Wolfe Research ● Initiated
Outperform 2026-02-24 Building track record
Truist Securities — Reiterated
Buy → Buy 2026-01-29 Building track record
Truist Securities — Reiterated
Buy → Buy 2026-01-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
12/30
Consensus clarity
27/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →